The Cigna Group (CI): A Bull Case Theory 

We came across a bullish thesis on The Cigna Group on The Passive Income Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on CI. The Cigna Group’s share was trading at $272.21 as of January 19th. CI’s trailing and forward P/E were 12.05 and 8.94 respectively according to Yahoo Finance.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. CI represents a compelling cash-flow–driven investment opportunity in the healthcare sector, largely overlooked as market attention remains fixated on GLP-1 drugs and regulatory headlines. Beneath the noise, Cigna has steadily evolved into what can best be described as a “cash flow utility,” powered primarily by its Evernorth health services division.

Evernorth, anchored by Cigna’s scaled Pharmacy Benefit Manager (PBM) platform, plays a critical role in managing and controlling healthcare costs for employers, insurers, and government programs, making it increasingly indispensable in an inflationary healthcare environment. This positioning provides resilience and predictability that the market often underappreciates.

From a financial perspective, Cigna’s cash generation is the core of the thesis. The company is targeting over $10 billion in annual distributable free cash flow, while its dividend obligation is only around $2 billion, resulting in an exceptional coverage ratio of roughly 5x. This conservative payout, reflected in a low payout ratio of approximately 19%, is intentional.

Rather than prioritizing yield, management has focused on balance sheet strength, disciplined deleveraging following large acquisitions, and returning capital through share repurchases and selective strategic M&A. Debt metrics have steadily improved, with declining debt-to-capitalization and strong interest coverage, further reinforcing financial flexibility.

Although Cigna is a relatively newer dividend grower compared to traditional healthcare aristocrats, its dividend growth trajectory is robust and well-supported by cash flow. The stock is frequently pressured by political and regulatory concerns, particularly around Medicare Advantage, creating periodic dislocations. These sell-offs present attractive entry points for long-term investors, with value emerging meaningfully below $340. As Medicare Advantage rates are finalized, clarity on this front could serve as a catalyst, reinforcing Cigna’s profile as a durable, undervalued cash compounder.

Previously, we covered a bullish thesis on The Cigna Group (CI) by Antonio Linares in May 2025, which highlighted the company’s structural PBM advantages, strategic partnerships with Eli Lilly and Novo Nordisk, and ongoing free cash flow compounding. CI’s stock price has depreciated by approximately 12.94% since our coverage due to market focus on regulatory uncertainties and GLP-1 drug . The Passive Income Portfolio shares a similar perspective but emphasizes CI’s evolution into a cash-flow utility and the resilience of its Evernorth division as a core driver of value.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.